Episode 4
748 Words
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found here.
https://www.ft.com/content/c21e2053-0373-4b8e-80b7-fad10f235604
So was coronavirus. From a few dozen daily cases in early June — even zero on June 9 — new Covid infections twice hovered near 6,000 this week, the highest daily rate in six months. Having won early access to supplies of the BioNTech/Pfizer jab in exchange for sharing nationwide data on how mass vaccination drives affect the pandemic, Israel is a closely watched indicator for where well-inoculated developed economies are heading. After months of euphoria, the data out of Israel is troubling. The Israeli ministry of health has twice revised downwards the long-term efficacy of the jabs — from the advertised 94 per cent protection from asymptomatic infections against the then-dominant Alpha variant, to as low as 64 per cent against the now-dominant Delta variant.
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found here.
https://www.ft.com/content/c21e2053-0373-4b8e-80b7-fad10f235604
So was coronavirus. From a few dozen daily cases in early June — even zero on June 9 — new Covid infections twice hovered near 6,000 this week, the highest daily rate in six months. Having won early access to supplies of the BioNTech/Pfizer jab in exchange for sharing nationwide data on how mass vaccination drives affect the pandemic, Israel is a closely watched indicator for where well-inoculated developed economies are heading. After months of euphoria, the data out of Israel is troubling. The Israeli ministry of health has twice revised downwards the long-term efficacy of the jabs — from the advertised 94 per cent protection from asymptomatic infections against the then-dominant Alpha variant, to as low as 64 per cent against the now-dominant Delta variant.
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found here.
https://www.ft.com/content/c21e2053-0373-4b8e-80b7-fad10f235604
So was coronavirus. From a few dozen daily cases in early June — even zero on June 9 — new Covid infections twice hovered near 6,000 this week, the highest daily rate in six months. Having won early access to supplies of the BioNTech/Pfizer jab in exchange for sharing nationwide data on how mass vaccination drives affect the pandemic, Israel is a closely watched indicator for where well-inoculated developed economies are heading. After months of euphoria, the data out of Israel is troubling. The Israeli ministry of health has twice revised downwards the long-term efficacy of the jabs — from the advertised 94 per cent protection from asymptomatic infections against the then-dominant Alpha variant, to as low as 64 per cent against the now-dominant Delta variant.
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found here.
https://www.ft.com/content/c21e2053-0373-4b8e-80b7-fad10f235604
So was coronavirus. From a few dozen daily cases in early June — even zero on June 9 — new Covid infections twice hovered near 6,000 this week, the highest daily rate in six months. Having won early access to supplies of the BioNTech/Pfizer jab in exchange for sharing nationwide data on how mass vaccination drives affect the pandemic, Israel is a closely watched indicator for where well-inoculated developed economies are heading. After months of euphoria, the data out of Israel is troubling. The Israeli ministry of health has twice revised downwards the long-term efficacy of the jabs — from the advertised 94 per cent protection from asymptomatic infections against the then-dominant Alpha variant, to as low as 64 per cent against the now-dominant Delta variant.
- Writer
